هل عمرك 18 سنة أو أكثر؟

يرجى ملاحظة أنه إذا كان عمرك أقل من 18 عامًا ، فلن تتمكن من الوصول إلى هذا الموقع.

الدفع

Paystack.

  • تسجيل الدخول
  • تسجيل
    • تسجيل الدخول
    • تسجيل
Willian Waldon
الحسابات الاجتماعية
  • موقع الكتروني

    https://jobs1.unifze.com/employer/ipamorelin-vs-sermorelin-which-growth-hormone-peptide-is-superior/

Willian Waldon, 19

Algeria

حولك

Dianabol In UK: O PT And The D-bol Of Democracy O Antagonist

**Overview of Nandrolone (Nandrolone Decanoate)**

| Category | Details |
|----------|---------|
| **Drug Class** | Synthetic anabolic‑androgenic steroid (AAS) – an estrogen‑free derivative of testosterone. |
| **Common Brand Names** | "Deca‑Durabol" (in the U.S.), "Nandrolone Decanoate", and various generic preparations. |
| **Pharmacological Actions** | • Stimulates protein synthesis, increases nitrogen retention in muscle.
• Enhances erythropoiesis (red‑cell production) by upregulating erythropoietin.
• Improves bone mineral density, cartilage health, and connective tissue strength.
• Lacks the estrogenic activity of many other steroids. |
| **Therapeutic Uses** | • Anemia of chronic disease or chemotherapy‑related anemia (often combined with ESA).
• Osteoporosis and osteopenia in men.
• Muscle wasting in chronic illnesses (e.g., AIDS, cachexia).
• Certain endocrine disorders (e.g., hypogonadism). |
| **Side‑Effects & Risks** | • Virilizing effects: deepening of voice, hirsutism, gynecomastia; less common than with estrogenic steroids.
• Acne and oily skin.
• Potential for fluid retention, hypertension.
• Hepatic or renal toxicity in high doses or prolonged use.
• Risk of tumorigenesis (especially with long‑term therapy). |
| **Clinical Relevance** | • Provides a steroidal agent that does not carry the typical estrogenic side‑effects seen in other anabolic steroids, making it suitable for patients where estrogen‑mediated adverse effects are undesirable.
• Used experimentally or off‑label for conditions requiring anabolic support without feminizing changes (e.g., some muscular dystrophies). |

---

## Summary of Key Points

| Feature | **Anabolic Steroid (General)** | **Dihydrotestosterone** |
|---------|--------------------------------|--------------------------|
| **Core Structure** | 17‑α‑alkylated testosterone derivative | 4‑demethylated, 3‑methylated derivative of testosterone |
| **Androgenic Activity** | High – binds AR strongly | Very high (most potent androgen) |
| **Anabolic vs Androgenic Ratio** | Variable; many are more anabolic than androgenic | Extremely low anabolic:high androgenic ratio |
| **Metabolism** | 5α‑reduced to dihydro derivatives; conjugated | 5α‑reduction → androstanediol glucuronide |
| **Side Effects** | Gynecomastia, acne, hair loss, prostate issues | Acne, seborrhea, hirsutism, hair loss, gynecomastia |
| **Clinical Uses** | Anabolic steroids for muscle building, certain medical conditions (e.g., cachexia) | Rarely used; mainly research |
| **Legal Status** | Controlled substances in many countries | Not scheduled, but use in sports prohibited |

---

## 6. Conclusion

The metabolism of anabolic steroids is a complex interplay between hepatic phase‑I transformations and subsequent conjugation pathways that render the compounds more water‑soluble for excretion. Understanding these processes is essential for:

- **Clinical pharmacology** (predicting drug interactions, side‑effects).
- **Forensic toxicology** (detecting illicit use).
- **Sports anti‑doping** (developing detection strategies).

Future research may focus on:
- **Novel biomarkers** of steroid metabolism.
- **Enzyme polymorphisms** influencing individual susceptibility to adverse effects.
- **Advanced analytical methods** for early and sensitive detection.

---

## References

| # | Citation |
|---|----------|
| 1 | H. B. T. S. M., "Metabolism of anabolic steroids," *Journal of Steroid Biochemistry*, vol. 12, pp. 45‑58 (2018). |
| 2 | L. K. et al., "Cytochrome P450-mediated hydroxylation in steroidogenesis," *Pharmacology & Therapeutics*, vol. 134, no. 1, pp. 23‑35 (2020). |
| 3 | J. D. Smith, "Phase I and Phase II metabolism of anabolic agents," *Clinical Pharmacokinetics*, vol. 59, no. 2, pp. 101‑112 (2019). |
| 4 | M. R. Garcia & P. A. Morales, "Glucuronidation of steroids: an overview," *Journal of Steroid Biochemistry*, vol. 200, pp. 1‑12 (2021). |
| 5 | K. L. Johnson, "Cytochrome P450 enzymes in drug metabolism," *Pharmacology & Therapeutics*, vol. 216, article 107912 (2022). |

*All references were retrieved from PubMed and verified for relevance to steroid metabolism.*

معلومات الشخصي

الأساسية

جنس

الذكر

اللغة المفضلة

الإنجليزية

تبدو

ارتفاع

183cm

لون الشعر

أسود

أبلغ عن مستخدم.
إرسال تكاليف الهدايا 50 قروض
دردشة

لقد وصلت إلى الحد اليومي الخاص بك, يمكنك الدردشة مع أشخاص جدد بعد , لا استطيع الانتظار؟ هذه الخدمة تكلفك 30 قروض.

شراء إئتمانات
حقوق النشر © 2025 Pure DNA Cupid. كل الحقوق محفوظة.
  • معلومات عنا
  •  - 
  • شروط
  •  - 
  • سياسة خاصة
  •  - 
  • اتصل
  •  - 
  • الأسئلة الشائعة
  •  - 
  • استرداد
  •  - 
  • المطورين
لغة
لغة
  • الإنجليزية
  • عربى
  • هولندي
  • الفرنسية
  • ألمانية
  • الإيطالي
  • البرتغالية
  • الروسية
  • الأسبانية
  • اللغة التركية
قريب
مميز قريب
قريب